Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Adac Research PA

Neither a doctor nor a teaching hospital

Research payments

$1,260,535

751 payments

Through program year 2025, Adac Research PA is reported as receiving $1,260,535 in research payments, across 751 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $184,154 336
2024 Research $198,959 314
2023 Research $237,851 30
2022 Research $154,448 18
2021 Research $136,539 25
2020 Research $163,121 17
2019 Research $185,463 11

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $609,778 28 payments
  2. Genzyme Corporation $256,598 46 payments
  3. Genentech, Inc. $90,195 31 payments
  4. Shionogi Inc $65,701 12 payments
  5. Regeneron Pharmaceuticals, Inc. $65,378 590 payments
  6. AstraZeneca AB $57,597 4 payments
  7. Sanofi US Services Inc. $44,672 32 payments
  8. Merck Sharp & Dohme Corporation $30,703 4 payments
  9. Novartis Pharmaceuticals Corporation $25,289 2 payments
  10. AstraZeneca UK Limited $13,075 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma $255,304 42 payments
  2. A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma. $169,900 8 payments
  3. A Multicentre Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma $147,235 6 payments
  4. A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler $125,381 5 payments
  5. A Multicenter,Single arm,Open label,Post Authorization,Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants with Severe Asthma including Several Under Studied Populations in the United States $92,998 3 payments
  6. Assessing Long-Term Outcomes of DUPIXENT Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyposis (AROMA) $65,378 590 payments
  7. Phase Iia $59,528 7 payments
  8. Evaluation of S-600918 in Adults With Refractory Chronic Cough $59,121 9 payments
  9. A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma. $57,597 4 payments
  10. The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod $41,094 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record